A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum
tolerated dose (MTD), and determine the Recommended Phase 2 Dose (RP2D) of PF-05082566, a
4-1BB agonist monoclonal antibody (mAb), in combination with MK-3475, a PD-1 inhibitor in
patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Antibodies, Monoclonal Immunoglobulin G Pembrolizumab